黑色素对肥胖小鼠的抗氧化作用
Luiza Martins Longaretti1, Marina Lummertz Magenis1, Adriani Paganini Damiani1
1Laboratory of Translational Biomedicine, Graduate Program of Health Sciences, University of Southern Santa Catarina - UNESC, Criciúma, SC, Brazil.
Mutagenesis
|February 10, 2026
概括
黑素 (MEL) 补充剂有效地降低了肥胖引起的炎症,DNA损伤和胰岛素抵抗,在食高脂肪食堂饮食 (CAF) 的小鼠中. 这项研究强调了MEL.
科学领域:
- 生物化学 生物化学
- 遗传学 遗传学 是一个
- 营养科学 营养科学
背景情况:
- 与超加工食品消费相关的肥胖率上升.
- 肥胖会损害抗氧化剂防御,增加DNA损伤的风险.
- 黑色素 (MEL) 显示出潜在的抗氧化和抗炎功效.
研究的目的:
- 评估MEL对食堂饮食 (CAF) 的小鼠生物化学,基因毒性和炎症标志物的影响.
- 调查MEL在缓解肥胖相关并发症中的作用.
主要方法:
- 60只雄性瑞士小鼠在17-21周内接受标准饮食 (SD) 或CAF养.
- 这些组在不同时间段接受了MEL补充剂.
- 评估DNA损伤 (彗星测试,微核测试),脂质概况,肝功能,炎症标志物 (TNF-α,IL-10),葡萄糖和胰岛素耐受性.
- 通过Western blot分析了氧化应激和DNA修复途径.
主要成果:
- CAF饮食诱导炎症,改变脂质/肝脏特征,DNA损伤和胰岛素抵抗.
- 17周的MEL补充剂逆转了CAF引起的变化.
- 与MEL减弱的CAF相关的氧化应激和组织损伤.
- MEL调节的DNA修复蛋白,减轻遗传毒性.
结论:
- 黑素 (MEL) 作为一种强大的抗氧化剂,可以对抗与肥胖相关的损害.
- 服用MEL补充剂有望减少与肥胖相关的生物化学和遗传改变.
- MEL可能是管理肥胖并发症的有价值的治疗策略.
相关概念视频
01:24Obesity
1.4K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.4K
01:21Drug Dosing: Obese Patients
269
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
269
02:19Buffer Effectiveness
55.5K
Buffer solutions do not have an unlimited capacity to keep the pH relatively constant . Instead, the ability of a buffer solution to resist changes in pH relies on the presence of appreciable amounts of its conjugate weak acid-base pair. When enough strong acid or base is added to substantially lower the concentration of either member of the buffer pair, the buffering action within the solution is compromised.
The buffer capacity is the amount of acid or base that can be added to a given volume...
The buffer capacity is the amount of acid or base that can be added to a given volume...
55.5K
03:26Framing Effects
8.0K
Information is everywhere and its presentation—such as how and when items are presented—can impact our perceptions and decisions surrounding the info. This broad concept umbrellas framing effects—influences that occur due to the way information is framed in its appearance, whether it’s purely the order or the specific wording of a message. Let’s take a look at numerous ways in which two versions of something can objectively say the same thing, yet we respond in...
8.0K
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
293
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
293
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
194
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
194